The study of risk in pulmonary arterial hypertension

European Respiratory Review

Volumn 21, Issue 125, 2012, Pages 234-238

  Rubin, Lewis J ^a   Simonneau, Gerald ^b   Badesch, David ^c   Galiè, Nazzareno ^d   Humbert, Marc ^b   Keogh, Anne ^e   Massaro, Joseph ^f   Cerinic, Marco Matucci ^g,h   Sitbon, Olivier ^b   Kymes, Steven ⁱ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c BOSTON UNIVERSITY   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BICÊTRE HOSPITAL   (France)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g AOUC   (Italy)

^h UNIVERSITY OF FLORENCE   (Italy)

ⁱ ST VINCENT S HOSPITAL   (Australia)

Author keywords

Economics; Prognosis; Pulmonary arterial hypertension; Quality of life; Risk; Survival

Indexed keywords

BOSENTAN; GENERIC DRUG; PROSTACYCLIN; SILDENAFIL;

AGE; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DISEASE COURSE; HEALTH CARE COST; HEALTH CARE POLICY; HEART RATE; HEART STROKE VOLUME; HUMAN; MEDICAL RESEARCH; PROGNOSIS; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; PULSE PRESSURE; QUALITY OF LIFE; REIMBURSEMENT; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SURVIVAL RATE; TREATMENT OUTCOME;

COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; HEALTH CARE COSTS; HEALTH POLICY; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; PROGNOSIS; PULMONARY ARTERY; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84865718686     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00003712     Document Type: Review

References (26)

1. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
2. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164-172.
3. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.
4. Humbert M, Sitbon O, Yaïci A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hyper- tension. Eur Respir J 2010; 36: 549-555.
5. Benza RL, Gomberg-Maitland M, Miller DP, et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest 2012; 141: 354-362.
6. Palazzini M, Leci E, Bachetti C, et al. Current era survival of pulmonary arterial hypertension (PAH) patients: comparison between clinical sub-groups. Eur Heart J 2010; 31: 21.
7. Humbert M, Yaici A, de Groote P, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011; 63: 3522-3530.
8. Layton G, Grieve A, Rubin LJ, et al. Short term response to sildenafil therapy for pulmonary arterial hypertension is associated with long term outcome. Am J Respir Crit Care Med 2011; 183: A5898.
9. Pittrow D, Vonk-Noordegraaf A, Vachiery J-L, et al. International, prospective registry for the documentation of first-line and maintenance therapy in patients with pulmonary hypertension (CompERA-XL): aims, design, methods, and baseline characteristics of patients. Am J Respir Crit Care Med 2010; 181: A4806.
10. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987; 107: 216-223.
11. Champion H, Mathier M, Maurey J, et al. Relationship between baseline pulmonary capillary wedge pressure and response to sildenafil treatment in pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 185: A4792.
12. Liu D, Liu Q-Q, Eyries M, et al. Molecular genetics and clinical features of Chinese idiopathic and heritable pulmonary arterial hypertension patients. Eur Respir J 2012; 39: 597-603.
13. McGoon M, Benza RL, Frost AE, et al. Validation of the French pulmonary hypertension network equation to estimate survival: a REVEAL analysis. Am J Respir Crit Care Med 2012; 185: A3828.
14. Nickel N, Golpon H, Greer M, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2012; 39: 589-596.
15. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219-1263.
16. Prospective longitudinal study of patients with idiopathic pulmonary arterial hypertension, family or taking anorectics (EFORT). NCT01185730. www.clinicaltrials.gov/ct2/show/NCT01185730 Date last accessed: May 2012. Date last updated: July 1, 2012.
17. Simonneau G, Rubin LJ, Galiè N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008; 149: 521-530.
18. A study of first-line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH) (AMBITION). NCT01178073. www.clinicaltrials.gov/ct2/show/NCT01178073 Date last accessed: May 2012. Date last updated: December 8, 2011.
19. Effects of the combination of bosentan and sildenafil versus sildena-fil monotherapy on pulmonary arterial hypertension (PAH) (COMPASS-2 study). NCT00303459. www.clinicaltrials.gov/ct2/show/NCT00303459 Date last accessed: May 2012. Date last updated: February 17, 2012.
20. Assess the efficacy and safety of sildenafil when added to bosentan in the treatment of pulmonary arterial hypertension. NCT00323297. www.clinicaltrials.gov/ct2/show/NCT00323297 Date last accessed: May 2012. Date last updated: June 15, 2012.
21. Sitbon O, Jais X, Savale L, et al. Upfront triple combination therapy of i.v. epoprostenol with oral bosentan and sildenafil in idiopathic and heritable pulmonary arterial hypertension. Am J Respir Crit Care Med 2011; 183: A5910.
22. Drummond MF, Sculpher MJ, Torrance GW, et al. eds. Methods for the Economic Evaluation of Health Care Programmes. 3rd Edn. Oxford, Oxford University Press, 2005.
23. Chen YF, Jowett S, Barton P, et al. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Health Technol Assess 2009; 13: 1-320.
24. McKenna SP, Doughty N, Meads DM, et al. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res 2006; 15: 103-115.
25. Murawski M, Frantz R, Gomberg-Maitland M, et al. Establishing the need for development of a patient reported outcome instrument in pulmonary arterial hypertension. Chest 2011; 140: A711.
26. Chen H, Gold W, De Marco T, et al. Development of a new patient-reported outcome measure to estimate functional capacity in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 185: A3833.